mapping the effectiveness and risks of glp-1 receptor agonists pdf agonism: a transformative approach for managing type-2 diabetes obesity | Saudi Pharmaceutical Journal Bridging the gap between GLP1-receptor

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

These phenomena, coupled with the re-development of overweight or obesity and poor glycaemic control when not on therapy, might increase the long-term risk of complications

In addition to GLP-1 injectables, we also prescribe oral medications like Phentermine , Qsymia , and Contrave when appropriate

Colvin et al., 2020), and to disrupt the normal activity of dopamine neurons during drug engagement (Egecioglu et al., 2013a

Batista AF, Bodart V, De FFG, Ferreira ST

161 However, these problems have not been shown to have a clear causal relationship with GLP-1RA in the general population, and there is a lack of data specific to the MASLD population, especially in individuals without co-existing T2DM